SCHEMBL723675

SCHEMBL723675

Fc1ccc(-c2ccc3ccnc(-c4ccc5[nH]ccc5c4)c3c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
MTOR P42345 1/20 0.47
NPC1 O15118 2/20 0.47
AHR P35869 2/20 0.46
CYP17A1 P05093 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
MAP3K11 Q16584 2/20 0.44
GRIA1 P42261 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
DYRK1A Q13627 2/20 0.40
DYRK2 Q92630 2/20 0.40
DYRK1B Q9Y463 2/20 0.40
CLK1 P49759 1/20 0.40
NISCH Q9Y2I1 1/20 0.40
TNIK Q9UKE5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723954 0.96 AHR (0.47) PIK3CDPIK3CAMTORNPC1AHR
SCHEMBL725225 0.92 MAP3K11 (0.50) NPC1CYP17A1CYP11B1CYP11B2MAP3K11
SCHEMBL31256758 0.92 MAP3K11 (0.50) NPC1CYP17A1CYP11B1CYP11B2MAP3K11
SCHEMBL786541 0.83 NPC1 (0.44) NPC1AHRGRIA1PDE3BPDE3A
SCHEMBL724718 0.82 PDE3B (0.46) PIK3CAMTORNPC1PDE3BPDE3A
SCHEMBL856313 0.80 AHR (0.70) PIK3CDPIK3CAMTORNPC1AHR
SCHEMBL29895884 0.80 NPC1 (0.53) NPC1AHRCYP17A1CYP11B1CYP11B2
SCHEMBL17732364 0.79 MAP3K11 (0.40) PIK3CDPIK3CAMTORNPC1CYP17A1
SCHEMBL15151753 0.79 MAP3K11 (0.40) PIK3CDPIK3CAMTORNPC1AHR
SCHEMBL723823 0.79 MAP3K11 (0.59) MAP3K11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US claimed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US claimed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US claimed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
EP-3793548-A1 COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER University of Tennessee Research Foundation (US) 2021-03-24 EP disclosed
CN-112512522-A Compounds for the treatment of triple negative breast and ovarian cancer 田纳西大学研究基金会 2021-03-16 CN disclosed
CN-112437664-A Compounds for the treatment of pancreatic cancer 田纳西大学研究基金会 2021-03-02 CN disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PIK3CD 1575/4885PIK3CA 403/4885MTOR 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.